In the high-stakes world of clinical genetics, the term “diagnostic odyssey” is more than just a phrase; it describes the often years-long, emotionally taxing journey that patients—particularly children with undiagnosed rare diseases—endure as they move from specialist to specialist in search of an answer. A new study published in Human Genetics and Genomics Advances (HGGA) suggests that shifting the paradigm of diagnostic testing could fundamentally change this narrative.
In a recent interview with the editors of HGGA, Dr. Tamara Roman, a Variant Analyst at UNC Health, discussed her pivotal research, titled “Exome sequencing early in outpatient evaluation in NCGENES 2: Changing the course of the diagnostic odyssey?” The study highlights the potential of deploying exome sequencing (ES) earlier in the outpatient clinical workflow, rather than treating it as a “last resort” test.
The Core Objective: Challenging the Clinical Status Quo
The central premise of Dr. Roman’s research—and the NCGENES 2 project as a whole—is that waiting to perform genomic testing until traditional diagnostic avenues have been exhausted is a systemic inefficiency that harms patients.
“I started this project as a postdoc,” Dr. Roman explains. “My interests have always been centered on variant classification and investigating the real-world clinical utility and impact of exome sequencing. We wanted to see if moving this technology to the front of the line could spare families the exhaustion of the traditional diagnostic odyssey.”
The study addresses the critical intersection between advanced laboratory technology and bedside clinical care. By integrating exome sequencing into the early stages of an outpatient evaluation, the research team sought to determine if they could shorten the time to diagnosis, thereby reducing both the financial burden on the healthcare system and the psychological strain on families.
A Collaborative Blueprint: The NCGENES 2 Framework
One of the most notable aspects of the study is its multidisciplinary design. Modern genomic medicine is rarely a solo endeavor, and Dr. Roman is quick to emphasize the collective effort behind the findings.
“I appreciate that this was a deeply collaborative research project,” says Dr. Roman. “It required a synchronized effort from clinical geneticists, laboratory geneticists, genetic counselors, research faculty, and students. I really enjoyed the synthesis of the research and the clinical components—seeing how the data we analyze in the lab translates directly into the care a patient receives.”
The Chronology of the Study
- Phase I: Enrollment and Baseline Evaluation. Patients entering the outpatient clinical setting were identified for early-intervention genomic screening.
- Phase II: Exome Sequencing Application. Instead of waiting for months of metabolic testing or imaging, exome sequencing was introduced as a primary tool to identify pathogenic or likely pathogenic variants.
- Phase III: Longitudinal Review. The team conducted follow-ups to assess the diagnostic yield and the clinical actions taken based on the genetic findings.
- Phase IV: Reclassification Analysis. The study underscored the importance of revisiting data as science advances, ensuring that initial findings are updated with the latest clinical knowledge.
Navigating the Gray Zone: The Challenge of VUS
While the promise of exome sequencing is immense, the reality of clinical interpretation remains complex. A major theme in Dr. Roman’s work is the persistent challenge of Variants of Uncertain Significance (VUS).
“Exome sequencing is incredibly useful for identifying pathogenic variants in conditions with a clear genetic etiology,” Dr. Roman notes. “However, we frequently encounter variants where the clinical significance is unclear. These VUS are challenging to interpret, particularly when there is limited phenotypic or functional data to support a definitive conclusion.”
This finding points to a broader systemic issue: the necessity for ongoing, iterative re-evaluation of genomic data. As the scientific community learns more about the human genome, variants that were once classified as “uncertain” often move into the “pathogenic” or “benign” categories.
“This highlights the importance of periodically evaluating emerging data,” Dr. Roman adds. “The diagnostic odyssey doesn’t necessarily end with the receipt of a sequencing report. It ends when we have the evidence to definitively act on that information, which often requires a commitment to long-term data surveillance.”
The Evolution of the Genetics Workforce
For young scientists like Dr. Roman, the rapid pace of advancement in genomics is both a career-defining opportunity and a significant hurdle. When asked about the challenges faced by early-career professionals in this field, the answer is clear: the sheer volume of information.
“The field of genetics is evolving at a breakneck speed,” she admits. “It can be incredibly challenging to stay updated and familiar with novel technologies, increasing data loads, and the shifting landscape of regulatory and clinical standards.”
Despite these challenges, the excitement for the field remains palpable. The ability to manipulate and interpret the building blocks of life is creating a new era of personalized medicine, but it requires a new generation of scientists who are comfortable with the uncertainty inherent in pioneering technology.
Beyond the Lab: Fascinating Frontiers in Genetic Engineering
Dr. Roman’s passion for her work extends to the broader implications of genetics in environmental and public health. When asked about the most fascinating development she has encountered in the past year, she points to a groundbreaking study by Dr. Kevin Esvelt and his team at MIT.
The research involves the concept of “heritable immunization” in mice to combat Lyme disease. By genetically engineering mice to produce monoclonal antibodies against the bacteria that causes Lyme disease, the researchers created a population that can pass this immunity down to subsequent generations.
“It is a fascinating intersection of synthetic biology and ecological control,” Dr. Roman remarks. “The idea that we can leverage genetic engineering to prevent the spread of zoonotic diseases by altering the host environment is a brilliant example of how our understanding of genetics can offer solutions to public health crises beyond human medicine.”
Implications for the Future of Clinical Practice
The findings presented in the NCGENES 2 study have significant implications for how healthcare systems handle patients with undiagnosed conditions. The study suggests that:
- Early Access is Cost-Effective: While the upfront cost of exome sequencing is high, it is arguably lower than the cumulative cost of years of inconclusive testing, specialist visits, and hospitalizations.
- Multidisciplinary Teams are Mandatory: The study confirms that the best outcomes occur when clinical and laboratory experts work in a tight feedback loop.
- The "Report" is a Living Document: Healthcare systems must move toward a model where genomic findings are re-assessed as new evidence emerges, rather than treating a sequencing report as a one-time event.
Conclusion
The work of Dr. Tamara Roman and her colleagues at NCGENES 2 represents a shift toward a more proactive, patient-centered model of genomic medicine. By advocating for earlier access to advanced diagnostics and highlighting the nuances of variant interpretation, they are helping to ensure that the “diagnostic odyssey” becomes a thing of the past.
As we look toward the future, the integration of such technologies will likely become the standard of care. However, as Dr. Roman emphasizes, the technology is only as good as the scientists behind it—those willing to engage with the complexity of the data, the necessity of collaboration, and the constant, rapid evolution of the scientific landscape.
For families waiting for answers, this research provides more than just data; it provides a roadmap to clarity and the hope that, through science, the shortest distance between a question and an answer is a well-designed genomic study.
About the Author
